Pancreatic Cancer Research

ResearcherAbramson Cancer CenterActive in the last 2 years

Erica L. Carpenter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0735-3605; OpenAlex author ID A5029750461; NIH RePORTER profile ID 10482845. Sources: funder_awards.

Their work

Papers
17 (first author 0, last author 4)
Trials
0
Grants
3
Labs led
1
Collaborators
85
Papers, trials and grants by year

2016: 1 grant · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 5 papers, 1 grant · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper, 1 grant · 2026: 2 papers

Papers 17

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ctm2.70573↗
  2. Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor … Co-author DOI 10.1158/1078-0432.ccr-25-3297↗
  3. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Co-author DOI 10.1002/cncr.35936↗
  4. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41467-024-49915-5↗
  5. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  6. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Co-author DOI 10.1158/1078-0432.ccr-23-1467↗
  7. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-20-1826↗
  8. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1200/po.22.00060↗
  9. Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28127↗
  10. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  11. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement. Co-author DOI 10.1158/1940-6207.capr-20-0403↗
  12. EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Co-author DOI 10.1158/1940-6207.capr-21-0161↗
  13. Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.145389↗
  14. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28099↗
  15. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adeno… Last author DOI 10.1158/1078-0432.ccr-19-3313↗
  16. miRNA Profiling of Magnetic Nanopore-Isolated Extracellular Vesicles for the Diagnosis of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3703↗
  17. Combining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes. Co-author DOI 10.1021/acsnano.7b05503↗

Grants 3

  1. Combining Machine Learning and Nanofluidic Technology for The Multiplexed Diagnosis of Pancreatic Adenocarcinoma R33CA278551↗
  2. Real-time monitoring of circulating pancreatic tumor cells and clusters R01CA207643↗
  3. Real-time Monitoring of Exosomes as a Biomarker for Pancreatic Cancer AWARD pancan:2016-erica-carpenter-mba-phd-real-time-monitoring-of-exosomes-as-a-bi

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jacob Edward Till · 10 shared papers, 2020–2026 · strength 1.45
  2. Mark H. O’Hara · 11 shared papers, 2017–2026 · strength 1.44
  3. David Aaron Issadore · 3 shared papers, 1 shared grant, 2017–2025 · strength 1.30
  4. Kim A. Reiss · 5 shared papers, 2021–2024 · strength 0.66
  5. Kenneth S. Zaret · 4 shared papers, 2021–2026 · strength 0.66
  6. Thomas Benjamin Karasic · 4 shared papers, 2022–2025 · strength 0.62
  7. Phyllis A. Gimotty · 3 shared papers, 2021–2026 · strength 0.53
  8. Peter James O'Dwyer · 4 shared papers, 2021–2024 · strength 0.51
  9. Charles M. Vollmer · 3 shared papers, 2020–2026 · strength 0.50
  10. Ben Z. Stanger · 5 shared papers, 2017–2024 · strength 0.46
  11. Bryson W. Katona · 4 shared papers, 2020–2022 · strength 0.44
  12. Ann L. Oberg · 2 shared papers, 2021–2026 · strength 0.41
  13. Shirsa Udgata · 3 shared papers, 2021–2022 · strength 0.38
  14. Neha Bhagwat · 4 shared papers, 2017–2024 · strength 0.36
  15. Samuele Cannas · 2 shared papers, 2024–2026 · strength 0.34
  16. Chen Yuan · 2 shared papers, 2024–2026 · strength 0.34
  17. Qiao-Li Wang · 2 shared papers, 2024–2026 · strength 0.34
  18. Brian Matthew Wolpin · 2 shared papers, 2024–2026 · strength 0.34
  19. Jonathan Andrew Nowak · 2 shared papers, 2024–2026 · strength 0.34
  20. Brianna M. Krusen · 1 shared paper, 2026 · strength 0.28
  21. Shounak Majumder · 1 shared paper, 2026 · strength 0.28
  22. Susan M. Domchek · 2 shared papers, 2021–2023 · strength 0.26
  23. Jennifer Rachel Eads · 2 shared papers, 2022–2024 · strength 0.25
  24. Jina Ko · 3 shared papers, 2017–2020 · strength 0.23
  25. Zev A. Wainberg · 2 shared papers, 2021–2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.